Streetbeat News

Revenues

CADE

Cadence Bank (NYSE:CADE) has received mixed analyst ratings over the past three months, with 2 bullish, 1 somewhat bullish, and 1 indifferent rating. The average 12-month price target is $33.25, up from the previous $29.33, indicating a potential increase of 13.37%. Analysts from Raymond James and Citigroup have adjusted their price targets, with Raymond James' Michael Rose changing his target from $35.00 to $34.00 and from $26.00 to $35.00, and Citigroup's Benjamin Gerlinger raising his from $27.00 to $32.00. Cadence Bank's financial performance shows a market cap below industry benchmarks, a revenue decline of -6.63%, a high net margin of 20.14%, an ROE of 2.11%, an ROA of 0.19%, and a debt-to-equity ratio of 0.93.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 12:00 pm

JCI

Johnson Controls Intl (NYSE:JCI) has been evaluated by 9 financial analysts over the past quarter, with opinions ranging from bullish to bearish. The average 12-month price target is $58.67, down from $59.33, with a high estimate of $66.00 and a low of $50.00. Analysts have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Johnson Controls, a company with a significant market presence, has seen a revenue decline of -3.18% and faces challenges in profitability and asset utilization, with a net margin of 7.95%, ROE of 3.34%, and ROA of 1.29%.

Portfolio Pulse from Benzinga Insights

January 31, 2024 | 12:00 pm

ADP

ADP projects its revenue growth for 2024 to be between 6-7%, with an adjusted EPS growth of 10-12%.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 11:58 am

NVO

Novo Nordisk (NYSE:NVO) has seen its market value surge to $506 billion, attributed to strong demand for its drugs Wegovy and Ozempic. The company's 2023 sales and operating profit have significantly increased, with sales growth of 18% to 26% expected in the current year. Despite reports of counterfeit drugs and competition from Eli Lilly, Novo Nordisk is confident in maintaining growth and is expanding production capacity.

Portfolio Pulse from Benzinga Neuro

January 31, 2024 | 11:57 am

SLGN

Silgan Holdings (SLGN) reported Q4 adjusted earnings per share of $0.63, surpassing the consensus estimate of $0.58. However, their quarterly sales of $1.34 billion fell short of the expected $1.39 billion, marking a 7.90% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 11:56 am

ZGN

Ermenegildo Zegna reported a significant increase in revenues for Q4 2023, reaching €570.36 million, up from €406.97 million in the previous year. The full-year revenues for 2023 were €1.9 billion, marking a 27.6% increase year-over-year, with organic growth of 19.3%. The fourth quarter saw an organic growth rate of 19.6%, showing an acceleration from the 11.3% growth in Q3 2023. The revenue boost was attributed to strong performance in the direct-to-consumer channels of both ZEGNA and Thom Browne brands.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 11:54 am

EVR

Evercore's financial performance shows a mixed outcome with a 6% decrease in advisory fees and a significant 57% decrease in underwriting fees year-over-year. However, the firm experienced a 4% increase in commissions and related revenue, along with a 9% increase in asset management and administration fees.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 11:48 am

EAT

Brinker International reported a 5.2% increase in Q2 comparable restaurant sales, with Chili's seeing a 5.0% rise and Maggiano's experiencing a 6.7% increase.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 11:48 am

BSX

Boston Scientific projects Q1 2024 net sales growth of 7.5%-9.5% year-over-year on a reported basis, and 7%-9% on an organic basis. The company anticipates adjusted EPS to be between $0.50 and $0.52, which is in line with the consensus estimate of $0.52.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 11:45 am

BSX

Boston Scientific projects net sales growth of 8.5%-9.5% year-over-year on a reported basis and 8%-9% on an organic basis for the full year 2024. The company anticipates adjusted EPS to be between $2.23 and $2.27, aligning with the consensus estimate of $2.24.

Portfolio Pulse from Benzinga Newsdesk

January 31, 2024 | 11:43 am